[Study on the reperfusion rate of acute myocardial infarction affected by inspiring nitric oxide and resolving thrombus intravenously before admission].
OBJECTIVE
To observe the reperfusion rate of acute myocardial infarction (AMI) affected by inspiring nitric oxide (NO) and resolving thrombus through veins.


METHODS
Sixty cases with AMI were randomly divided into test group (n=30) and control groups (n=30). Patients in test group were cured with NO (20+/-1)mg/L inspiration for 30 minutes at once before admission and urokinase (150x10(4) U) adding 0.9% sodium chloride intravenously injected within 30 minutes, while patients in control were treated with urokinase as the same method of the test group.


RESULTS
The reperfusion and non-reperfusion patients were 25 and 5 cases in test group, and they were 19 and 11 cases in control group. The reperfusion rate of AMI in test group was significantly higher than that in control group 83.3% vs. 63.3% (P<0.05). No peak periods of lactate dehydrogenase (LDH) and creatine phosphokinase (CPK) appeared in test group, and the difference was significant compared to the control group (P<0.05).


CONCLUSIONS
NO inspiration before urokinase is an effective method to treat AMI and advance the reperfusion rate.
Sun
Li-dong
LD
Emergency Department, the 155th Hospital of PLA, Kaifeng 475003, Henan, China. 666sld5028@163.com
Tang
You-lin
YL
Xi
Wei-bin
WB
Zhang
Nan
N
Zhang
Yin-zhu
YZ
D000368:Aged; D016022:Case-Control Studies; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D007275:Injections, Intravenous; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D015425:Myocardial Reperfusion; D009569:Nitric Oxide / Q000627:therapeutic use*; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D020246:Venous Thrombosis / Q000188:drug therapy*
D016166:Free Radical Scavengers; D009569:Nitric Oxide; D007770:L-Lactate Dehydrogenase; D003402:Creatine Kinase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator